Gain Therapeutics (NASDAQ:GANX – Get Free Report) and Creative Medical Technology (NASDAQ:CELZ – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.
Profitability
This table compares Gain Therapeutics and Creative Medical Technology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gain Therapeutics | N/A | -161.59% | -118.36% |
| Creative Medical Technology | N/A | -86.52% | -81.96% |
Institutional and Insider Ownership
12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by company insiders. Comparatively, 1.0% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gain Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
| Creative Medical Technology | 1 | 0 | 1 | 0 | 2.00 |
Gain Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 346.43%. Given Gain Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Gain Therapeutics is more favorable than Creative Medical Technology.
Risk and Volatility
Gain Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, Creative Medical Technology has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500.
Valuation and Earnings
This table compares Gain Therapeutics and Creative Medical Technology”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gain Therapeutics | N/A | N/A | -$20.16 million | ($0.50) | -3.36 |
| Creative Medical Technology | $10,000.00 | 636.07 | -$5.99 million | ($2.07) | -0.47 |
Creative Medical Technology has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.
About Gain Therapeutics
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
About Creative Medical Technology
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-american-depositary-shares-logo-1200x675.png){kind=logo}
